Novartis pays $150M to license Akcea-Ionis cardiac disease drug

Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial. TQJ230, formerly known as AKCEA-APO(a)-Lrx, is designed to lower levels of Lp(a) by inhibiting the production of apolipoprotein(a)
Read more...

;